In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.

Article Details

Citation

Copy to clipboard

Taavitsainen P, Kiukaanniemi K, Pelkonen O

In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.

Eur J Clin Pharmacol. 2000 May;56(2):135-40.

PubMed ID

10877007 [ View in PubMed

]

Abstract

OBJECTIVE: Metabolic interactions at the level of drug-metabolising enzymes are important for drug therapy. We investigated potential interactions of losartan, irbesartan, valsartan, eprosartan and candesartan with cytochrome P450 (CYP) enzymes in human liver microsomes. METHODS: In incubations with human liver microsomes in vitro, the inhibitory potency of angiotensin-II receptor antagonists (sartans) on CYP-specific model activities were compared by measuring the IC50 and, with respect to more potent inhibition, Ki values. RESULTS: None of the five sartans inhibited CYP2A6-, CYP2D6- or CYP2E1-associated activities (coumarin 7-hydroxylation, dextromethorphan O-demethylation and chlorzoxazone 6-hydroxylation, respectively) to any significant extent. Losartan and irbesartan inhibited the CYP2C9-associated tolbutamide methylhydroxylation more potently (Ki values 4.1 microM and 24.5 microM), than valsartan, candesartan or eprosartan (Ki values 135 microM, 155 microM and > 1000 microM, respectively). Losartan and irbesartan inhibited CYP1A2- and CYP3A4-associated activities (ethoxyresorufin O-deethylation and testosterone 6beta-hydroxylation) with relatively weak affinities (IC50 values between 200 microM and 500 microM). CYP2C1OFF S-mephenytoin 4'-hydroxylation activity was inhibited by losartan (IC50 value 138 microM) and much less or not at all by the other sartans tested. CONCLUSION: All sartans except eprosartan have at least some affinity for CYP2C9, but only losartan has an affinity for CYP2C19. Losartan and irbesartan have modest affinity for CYP1A2 and CYP3A4. This would suggest that the theoretical potential for drug interactions is likely to be quite low, with the possible exceptions of losartan and irbesartan for CYP2C9. Based on these findings, further studies on the interaction potential of losartan and irbesartan are warranted.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Candesartan	Cytochrome P450 2C9	Protein	Humans	Unknown	Substrate Inhibitor	Details
Irbesartan	Cytochrome P450 3A4	Protein	Humans	No	Inhibitor	Details
Losartan	Cytochrome P450 2C19	Protein	Humans	Unknown	Inhibitor	Details